MarketCap
Facebook
X
Telegram
Calithera Biosciences Revenue | CALA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Calithera Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 9.75 M | - | - | 22.3 M | 26 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26 M | 9.75 M | 19.3 M |
Quarterly Revenue Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6.75 M | 3 M | - | - | 6.75 M | 3 M | - | - | - | - | - | - | 22.3 M | 17.1 M | 5.19 M | - | 22.3 M | 17.1 M | 5.19 M | 7.25 M | 7.25 M | 7.26 M | 4.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.3 M | 3 M | 9.61 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
7.83 M | $ 5.65 | 6.11 % | $ 692 M |  USA |
 |
Фармсинтез
LIFE
|
372 M | - | - | - |  Russia |
 |
AbbVie
ABBV
|
16.6 B | $ 261.61 | 1.7 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 11.07 | 1.61 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
114 M | $ 7.08 | 2.07 % | $ 211 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
223 M | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
3 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
178 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
5.82 M | $ 5.38 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 33.41 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
7.67 M | $ 3.3 | 2.94 % | $ 195 M |  China |
 |
iTeos Therapeutics
ITOS
|
35 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
2.04 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 24.7 | 2.05 % | $ 3.75 B | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
642 K | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Cyclerion Therapeutics
CYCN
|
2.07 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58.9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 5.13 | 0.1 % | $ 983 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.09 | 2.35 % | $ 139 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
469 K | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
3.09 M | - | 17.91 % | $ 11.1 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.07 B | $ 27.54 | 0.04 % | $ 4.64 B | USA |
 |
AIM ImmunoTech
AIM
|
88 K | $ 0.22 | 1.52 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
510 M | $ 9.18 | 0.16 % | $ 2.19 B | USA |
 |
SQZ Biotechnologies Company
SQZ
|
21.5 M | - | 57.95 % | $ 12.8 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Achieve Life Sciences
ACHV
|
5.06 M | $ 7.15 | 1.27 % | $ 312 M | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
22.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
2.32 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
2.72 M | - | - | $ 7.29 B | USA |
 |
AC Immune SA
ACIU
|
3.57 M | $ 2.67 | 2.6 % | $ 269 M | Schweiz |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 1.0 | 5.6 % | $ 257 M | USA |
 |
Alector
ALEC
|
21 M | $ 2.17 | 1.64 % | $ 224 M | USA |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 5.05 | 0.96 % | $ 49.9 M | USA |